<DOC>
	<DOCNO>NCT02261220</DOCNO>
	<brief_summary>This multicenter , open-label , dose-exploration dose-expansion study evaluate safety , tolerability , antitumor activity , PK immunogenicity MEDI4736 combination tremelimumab subject select advanced solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study MEDI4736 Combination With Tremelimumab Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Male female subject 18 year old Histologic confirmation advance solid tumor Subjects must recurrent/metastatic disease may previously treat recurrent/metastatic setting . Any concurrent chemotherapy , immunemediated therapy biologic hormonal therapy cancer treatment Active prior document autoimmune disease within past 2 year Current prior use immunosuppressive medication within 14 day exception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>